Abstract:Background: An inactivated poliomyelitis vaccine made from Sabin strains (sIPVs) has widely been used in China since 2015. However, the quantitative data on the instant and persistent inhibition effects of maternal poliovirus antibodies on the immune response to sIPV priming and booster vaccination have not been available yet. Objective: In this study, we aim to explore and quantify the instant and persistent inhibition effect of maternal poliovirus antibodies on the immune response elicited by sIPV primary and booster vaccination. Methods: The immunogenicity data consisting of the days 0 and 30 after the prime and booster vaccination of the sIPV in a phase IV trial were pooled for a quantitative analysis of the inhibition effect of maternal poliovirus antibody. The geometric mean ratio (GMR) was calculated using linear regression models, representing that every 2-fold higher maternal poliovirus antibody titer may result in a (1-GMR) lower postimmunization antibody titer. Results: The GMRs for poliovirus types 1, 2, and 3 were 0.79 (0.77–0.82), 0.85 (0.81–0.89), and 0.87 (0.83–0.91) at 30 days after the priming series, 0.86 (0.83–0.89), 0.81 (0.76–0.85), and 0.86 (0.80–0.93) at one year after the priming series, and 0.96 (0.94–0.99), 0.89 (0.86–0.93), and 0.98 (0.93–1.03) at 30 days after the booster dose. The inhibition effect continued to exist until the booster dose 1 year later, and such a persistent inhibition effect was almost attenuated for poliovirus types 1 and 3, and partly reduced for type 2 at 30 days after the booster dose. Conclusion: A wider interval between the four sIPV doses might be a consideration for reducing the effect of maternal antibodies and subsequently eliciting and maintaining higher antibody levels to protect against poliovirus transmission and infection at the final stage of polio eradication in the global world. This study's clinical trial registry number is NCT04224519.

What problem does this paper attempt to address?

The problem that this paper attempts to solve is: to analyze and quantify the immediate and continuous inhibitory effects of maternal poliovirus antibodies on the immune response after the primary and booster immunizations of Sabin - strain inactivated poliovirus vaccine (sIPV). Specifically, the study aims to explore how maternal antibodies affect the immune response of infants after sIPV vaccination and provide a basis for optimizing the immunization strategy of poliovirus vaccine, especially in the final stage of global polio eradication. ### Main problem analysis: 1. **Background and problem statement**: - Since 2015, China has widely used the Sabin - strain inactivated poliovirus vaccine (sIPV). However, there are no reported quantitative data on the immediate and continuous inhibitory effects of maternal poliovirus antibodies on the immune response after the primary and booster immunizations of sIPV. - Maternal antibodies are transferred to the fetus through the placenta, providing passive immunity within several months after the newborn is born, but may also inhibit the infant's immune response to the vaccine. 2. **Research objectives**: - Quantitatively analyze the immediate and continuous inhibitory effects of maternal poliovirus antibodies on the immune response after the primary and booster immunizations of sIPV. - Evaluate whether this inhibitory effect will affect the final antibody level and provide a basis for optimizing the immunization strategy of poliovirus vaccine. 3. **Research methods**: - Serum samples of 1,200 participants were collected, sampled on day 0 and day 30 before and after the primary immunization (at 2, 3, and 4 months of age) and the booster immunization (at 18 - 24 months of age). - The geometric mean ratio (GMR) was used to measure the effect of every 2 - fold increase in maternal antibody titer on the post - immunization antibody titer. 4. **Research results**: - Thirty days after the primary immunization, the GMRs of maternal antibodies to poliovirus types 1, 2, and 3 were 0.79 (0.77 - 0.82), 0.85 (0.81 - 0.89), and 0.87 (0.83 - 0.91), respectively, indicating that every 2 - fold increase in maternal antibody titer would lead to a 21%, 15%, and 13% decrease in the post - immunization antibody titer, respectively. - Thirty days after the booster immunization, the inhibitory effect of maternal antibodies on poliovirus type 1 was significantly weakened (GMR = 0.96, p = 0.003), while there was still a partial inhibitory effect on type 2 (GMR = 0.89, p < 0.001), and there was almost no inhibitory effect on type 3 (GMR = 0.98, p = 0.348). 5. **Conclusions**: - The study shows that maternal poliovirus antibodies have immediate and continuous inhibitory effects on the immune response after the primary and booster immunizations of sIPV, but this effect is weakened after the booster immunization. - It is recommended to extend the interval between the four doses of sIPV to reduce the influence of maternal antibodies, thereby increasing and maintaining a higher antibody level to protect children from poliovirus infection and spread. Through these analyses, this study provides an important scientific basis for optimizing the immunization strategy of poliovirus vaccine.

Quantitative Analysis of the Instant and Persistent Inhibition Effects of Maternal Poliovirus Antibodies on the Immune Response in a Phase IV Trial of a Sabin Strain-Based Inactivated Poliovirus Vaccine

Immunogenicity and lot-to-lot consistency of booster shot with Sabin inactivated poliomyelitis vaccine in Chinese children aged 18–24 Months: A phase IV clinical trial

Immune Persistence following Primary Immunization and the Immunogenicity and Safety of a Booster Dose of a Multidose Sabin Strain-Based Inactivated Polio Vaccine in Infants Aged 18 Months

Immunogenicity and safety of the inactivated poliomyelitis vaccine made from Sabin strains in a phase IV clinical trial for the vaccination of a large population

Safety and 6-month immune persistence of inactivated poliovirus vaccine (Sabin strains) simultaneously administrated with other vaccines for primary and booster immunization in Jiangxi Province, China

Immunogenicity and immune persistence in 4-year-old children completing four doses of Sabin strain or wild strain inactivated poliovirus vaccine: A phase IV, open-labeled, parallel-controlled observational study

Post hoc analysis of two clinical trials to compare the immunogenicity and safety of different polio immunization schedules in Chinese infants

Safety, immunogenicity, and lot-to-lot consistency of a multidose Sabin strain-based inactivated polio vaccine: a phase III, randomized, blinded, positive-control clinical trial in infants aged 2 months

Immune persistence after different polio sequential immunization schedules in Chinese infants

Immune Serum From Sabin Inactivated Poliovirus Vaccine Immunization Neutralizes Multiple Individual Wild and Vaccine-Derived Polioviruses

Immunogenicity of Two Different Sequential Schedules of Inactivated Polio Vaccine Followed by Oral Polio Vaccine Versus Oral Polio Vaccine Alone in Healthy Infants in China

A phase 3 randomized, open-label study evaluating the immunogenicity and safety of concomitant and staggered administration of a live, pentavalent rotavirus vaccine and an inactivated poliomyelitis vaccine in healthy infants in China

Nasal and pharyngeal mucosal immunity to poliovirus in children following routine immunization with inactivated polio vaccine (IPV) in the United States of America

Evaluation of the immunization effectiveness of bOPV booster immunization and IPV revaccination

Immuno-persistence after the fourth and fifth doses of inactivated polio vaccines in school-aged children

Effect of maternal immunisation with multivalent vaccines containing inactivated poliovirus vaccine (IPV) on infant IPV immune response: A phase 4, multi-centre randomised trial

Isolation and characterization of a Sabin 3/Sabin 1 recombinant vaccine-derived poliovirus from a child with severe combined immunodeficiency

Incidence rates of health outcomes of interest among Chinese children exposed to selected vaccines in Yinzhou Electronic Health Records: A population-based retrospective cohort study.

The Transfer and Decay of Maternal Antibodies Against Enterovirus A71, and Dynamics of Antibodies Due to Later Natural Infections in Chinese Infants: a Longitudinal, Paired Mother–neonate Cohort Study

Influence of gut microbiota on mucosal IgA antibody response to the polio vaccine

Inactivated Poliovirus Vaccine: Recent Developments and the Tortuous Path to Global Acceptance